BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...recently as VP corporate licenses, until 2014. Since then, Goupit has served on the boards of Inventiva S.A....
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...Calliditas Therapeutics AB (SSE:CALTX; NASDAQ:CALT), which raised $87.9 million in June; and French NASH company Inventiva S.A....
BioCentury | Aug 28, 2020
Product Development

Data Bytes: NASH pipeline still full despite high-profile setbacks

...Deal with Multiple MOAs”). After elafibranor’s failure, the most advanced PPAR ɑ/ƍ agonist is lanifibranor from Inventiva S.A....
...data from the NATIVE trial demonstrated that the therapy outperformed Ocaliva on several measures (see “Inventiva...
...proliferation activated receptor alphaPPAR ƍ –  Peroxisome proliferation activated receptor delta Amanda Micklus Intercept Pharmaceuticals Inc. Genfit S.A. Novartis AG Pfizer Inc. Inventiva S.A. Farnesoid...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc. (NASDAQ:PSTX) and Inventiva S.A....
...“Rubius Turns to Cancer, Autoimmune” ). Two other listings The aftermarket performances of Poseida and Inventiva...
...shares bracketed their $16 offering price during Friday trading, finishing down $0.65 to $15.35, while Inventiva’s...
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...series B round (see “Funding Clinical Programs, Manufacturing” ). Also due to trade Friday is Inventiva S.A....
...it would raise about $107.7 million. Inventiva’s pipeline includes treatments for non-alcoholic steatohepatitis and mucopolysaccharidoses. Inventiva’s...
...aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva S.A....
BioCentury | Jul 8, 2020
Finance

Data Bytes: IPO queue remains hot

...their proposed offerings; each now plan to sell 10 million shares at $14-$16 on NASDAQ. Inventiva S.A....
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...September 2019 series B round (see “Funding Clinical Programs, Manufacturing” ). French liver disease company Inventiva S.A....
...to treat NASH, driving a big gain for the company’s shares (see “Resuscitating Hopes” ; “Inventiva...
BioCentury | Jun 17, 2020
Product Development

Daily Chart: Inventiva vs. Intercept in NASH

...from Intercept, which is under FDA review with a decision expected after June 26 (see “Inventiva...
...EMA. The outcomes were primary endpoints in the Intercept trial and secondary endpoints in the Inventiva...
...an 18-month readout for obeticholic acid. Stephen Hansen, Associate Editor lanifibranor (iva337) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Inventiva S.A. Intercept...
BioCentury | Jun 16, 2020
Product Development

Inventiva resuscitates hopes for PPAR in NASH

...mechanism for NASH after two PPAR agonists failed to show a benefit. Now, data for Inventiva’s...
...addition to meeting the primary endpoint of a Phase II trial, the pan-PPAR agonist from Inventiva S.A....
...endpoint of the Phase IIb NATIVE trial data was reduction steatosis activity fibrosis (SAF) score. Inventiva...
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...for NASH and in Phase II studies for PBC and non-alcoholic fatty liver disease (NAFLD). Inventiva S.A....
Items per page:
1 - 10 of 32
BioCentury | Feb 3, 2021
Management Tracks

Lilly Asia’s Li joins AffaMed as president; plus moves at Actimed, Elicio, Life Biosciences, OncoNano, Tollys, HighTide and Patient Square Capital

...recently as VP corporate licenses, until 2014. Since then, Goupit has served on the boards of Inventiva S.A....
BioCentury | Oct 14, 2020
Management Tracks

Anderson joining Sofinnova Partners to bridge European biotechs to public markets

...Calliditas Therapeutics AB (SSE:CALTX; NASDAQ:CALT), which raised $87.9 million in June; and French NASH company Inventiva S.A....
BioCentury | Aug 28, 2020
Product Development

Data Bytes: NASH pipeline still full despite high-profile setbacks

...Deal with Multiple MOAs”). After elafibranor’s failure, the most advanced PPAR ɑ/ƍ agonist is lanifibranor from Inventiva S.A....
...data from the NATIVE trial demonstrated that the therapy outperformed Ocaliva on several measures (see “Inventiva...
...proliferation activated receptor alphaPPAR ƍ –  Peroxisome proliferation activated receptor delta Amanda Micklus Intercept Pharmaceuticals Inc. Genfit S.A. Novartis AG Pfizer Inc. Inventiva S.A. Farnesoid...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc. (NASDAQ:PSTX) and Inventiva S.A....
...“Rubius Turns to Cancer, Autoimmune” ). Two other listings The aftermarket performances of Poseida and Inventiva...
...shares bracketed their $16 offering price during Friday trading, finishing down $0.65 to $15.35, while Inventiva’s...
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...series B round (see “Funding Clinical Programs, Manufacturing” ). Also due to trade Friday is Inventiva S.A....
...it would raise about $107.7 million. Inventiva’s pipeline includes treatments for non-alcoholic steatohepatitis and mucopolysaccharidoses. Inventiva’s...
...aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta Inc. Relay Therapeutics Inc. Inventiva S.A....
BioCentury | Jul 8, 2020
Finance

Data Bytes: IPO queue remains hot

...their proposed offerings; each now plan to sell 10 million shares at $14-$16 on NASDAQ. Inventiva S.A....
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...September 2019 series B round (see “Funding Clinical Programs, Manufacturing” ). French liver disease company Inventiva S.A....
...to treat NASH, driving a big gain for the company’s shares (see “Resuscitating Hopes” ; “Inventiva...
BioCentury | Jun 17, 2020
Product Development

Daily Chart: Inventiva vs. Intercept in NASH

...from Intercept, which is under FDA review with a decision expected after June 26 (see “Inventiva...
...EMA. The outcomes were primary endpoints in the Intercept trial and secondary endpoints in the Inventiva...
...an 18-month readout for obeticholic acid. Stephen Hansen, Associate Editor lanifibranor (iva337) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Inventiva S.A. Intercept...
BioCentury | Jun 16, 2020
Product Development

Inventiva resuscitates hopes for PPAR in NASH

...mechanism for NASH after two PPAR agonists failed to show a benefit. Now, data for Inventiva’s...
...addition to meeting the primary endpoint of a Phase II trial, the pan-PPAR agonist from Inventiva S.A....
...endpoint of the Phase IIb NATIVE trial data was reduction steatosis activity fibrosis (SAF) score. Inventiva...
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...for NASH and in Phase II studies for PBC and non-alcoholic fatty liver disease (NAFLD). Inventiva S.A....
Items per page:
1 - 10 of 32